Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice

Briggs, Kelsey; Kirby, Cara; Beavis, Ashley C.; Zengel, James; Patil, Preetish; Sauder, Christian; He, Biao

doi:10.1128/jvi.01983-21

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this rate decreased to 62% among individuals aged 13–18 years. Additionally, immunity surveys conducted overseas have reported a significant decline in antibody levels and disparities in the avidity of mumps immunoglobulin G (IgG) over time post-vaccination, compared to measles and rubella [ 11 , 12 ]. Therefore, waning immunity post-vaccination emerges as a plausible explanation for the increased incidence of mumps despite high vaccination rates.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice

Kim,

Won,

Hwang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Mumps virus (MuV) causes an acute contagious human disease characterized by swelling of the parotid glands. Despite the near elimination of mumps in many countries, the disease has recurred, even in vaccinated populations, especially adolescents. Immunization effectivity of the genotype A vaccine strain Jeryl Lynn (JL) is declining as genotype A is no longer predominant; therefore, a new vaccine strain and booster vaccine are required. We generated a cell culture-adapted MuV genotype F called F30 and evaluated its immunogenicity and cross-protective activity against diverse genotypes. F30 genome nucleotide sequence determination revealed changes in the NP, L, SH, and HN genes, leading to five amino acid changes compared to a minimally passaged stock (F10). F30 showed delayed growth, smaller plaque size in Vero cells, and lower neurotoxicity in neonatal mice than F10. Furthermore, F30 was immunogenic to other genotypes, including the JL vaccine strain, with higher efficacy than that of JL for homologous and heterologous immunization. Further, F30 exhibited cross-protective immunity against MuV genotypes F and G in Ifnar−/− mice after a third immunization with F30 following two doses of JL. Our data suggest that the live-attenuated virus F30 could be an effective booster vaccine to control breakthrough infections and mumps epidemics.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice

Kim,

Won,

Hwang

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice

Yeon Kim,

Lee,

Hwang

et al. 2024

Vaccine: X

View full text Add to dashboard Cite

Circulation of Mumps Virus Genotype G in Pakistan During 2023 Outbreak

Umair,

Haider,

Jamal

et al. 2023

Future Virol.

View full text Add to dashboard Cite

Aim: Despite recurring mumps outbreaks in Pakistan, the virus's genomic diversity remains unavailable. This study explores the mumps genomic diversity in the 2023 Islamabad outbreak. Methods: During January and February 2023, 32 buccal/throat swabs were collected from suspected mumps cases. 15 tested mumps virus (MuV)-positive via RT-PCR. Positive samples underwent partial SH gene sequencing; a subset (n = 10) was whole-genome sequenced using Illumina MiSeq. Results: Phylogenetic analysis identified genotype-G, sharing 95.57–98.73% homology with Japanese/Canadian isolates. Whole-genome-sequencing (n = 2) confirmed genotype-G, 99% similar to Sheffield/Iowa strain. HN region displayed 95.01–95.36% identity with Jeryl Lynn, with genotype G-specific mutations, except T265I. Conclusion: This is the first report of partial and whole-genome sequencing of MuV from Pakistan, highlighting the necessity for genomic surveillance and vaccine integration.

show abstract

Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice

Cited by 3 publications

References 40 publications

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice

Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice

Circulation of Mumps Virus Genotype G in Pakistan During 2023 Outbreak

Contact Info

Product

Resources

About